Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis.

Health technology assessment (Winchester, England)

Volumn 14, Issue Suppl. 2, 2010, Pages 41-46

  Pitt, M ^a   Crathorne, L ^b   Moxham, T ^b   Bond, M ^b   Hyde, C ^b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EVEROLIMUS; RAPAMYCIN;

COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COST-BENEFIT ANALYSIS; ENGLAND; HUMANS; KIDNEY NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; WALES;

EID: 84886943015     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta14suppl2/06     Document Type: Review

References (0)